MLH uses hyperthermic intraperitoneal chemotherapy on ovarian cancer patient


On October 30, Lankenau Medical Center performed the first hyperthermic intraperitoneal chemotherapy for ovarian cancer at Main Line Health.  A patient of Dr. Brian Wojciechowski at Riddle Hospital was optimally resected and received two hours of high temperature chemotherapy in the operating room under the care of Drs. David Holtz and Ned Carp. This follows the publication this year of results from a randomized trial showing that this therapy gives women a five-month improvement in median recurrence free survival and a 12-month improvement in median overall survival.

This entry was posted in Clinician News and tagged , . Bookmark the permalink.

Leave a Reply

Your email address will not be published.